The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 1,810 studies for Anemia across more than 10 countries. 215 are recruiting or about to start. 1,106 of them are mainly about Anemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 22 narrower conditions too, such as Anemia, Sickle Cell: 4,772 studies, 830 open.
ClinicalTrials.gov finds 5,304 studies for Anemia.How that becomes 1,810 here
This page counts the studies the registry files under Anemia, and those it files under no condition that list Anemiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count
5,304Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−157List Anemia as a condition, but the registry did not file them under itMost often written as “Iron Deficiency (Without Anemia)” (16), “Renal Anemia” (8), and “Anemia of Chronic Kidney Disease” (6). The registry filed them under other conditions only, most often Iron Deficiencies (25) and Anemia, Neonatal (11).
−445Match it another way175 name it in the title, 92 in a keyword, and 178 by a synonym or other text the search reads.
1,810The count on this page140 of them list Anemia in their own words; the registry filed them under no condition.
Add Anemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time
Every program with a company-led study here in the last two years, whatever its size: 20 programs from 17 companies, 11 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare 3SBio, Shenzhen Salubris Pharmaceuticals and Biocad here →
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 4 in phase 3 with the nearest primary completion, of 20 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (5)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
1 Dec 2026 est.AND017· Kind Pharmaceuticals LLC · Phase 3main aim+ AND017 vs HematinicsNCT07487727 A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) — primary endpoint: Evaluate the efficacy of AND017 compared with the active control in maintaining Hemoglobin (Hb) levels in patients with anemia due to CKD · 240 enrolled
May 2027 est.daprodustat· Qilu Pharmaceutical Co., Ltd. · Phase 3main aimvs Darbepoetin alfaNCT07300111 A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) — primary endpoint: Mean Hemoglobin (Hgb) During the Efficacy Evaluation Period · 100 enrolled
May 2027 est.selcodebart· Disc Medicine, Inc · Phase 2named, not the main aimNCT05320198 Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia — primary endpoint: Safety and Tolerability of DISC-0974 (Phase 1b only) · 150 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Anemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
77studies finish main data collection within a year15 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger. 34 (28%) take children under 18. 12 (10%) are for women only and 1 (1%) for men only; 23 (19%) take healthy volunteers.
Across all 1,810 studies, recruiting or not: 35% stop at 75 or younger and 29% at 65; 26% take children; 13% are for women only and 2% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Anemia studies take
Of 149 phase 3 interventional studies under Anemia, half reached primary completion within 30 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
12 mo3–43 · 48 studies
6 mo3–30 · 34 studies
—
Phase 2
28 mo16–56 · 88 studies
23 mo13–40 · 58 studies
—
Phase 3
30 mo17–51 · 149 studies
25 mo15–49 · 98 studies
36 mo21–59 · 51 studies
Phase 4
27 mo17–48 · 73 studies
—
25 mo17–48 · 59 studies
Interventional, no phase
17 mo7–29 · 178 studies
—
18 mo8–30 · 164 studies
Observational
30 mo12–76 · 145 studies
—
30 mo11–83 · 124 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.